Skip to main content
Signal8
Launch Terminal

Tyra Biosciences, Inc. (TYRA)

Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Tyra Biosciences, Inc. logo

Tyra Biosciences, Inc.

NASDAQ:TYRAHealthcare
-1.91%$21.07
AH$21.07+0.00%vs close
Mkt Cap$1.45B
Float35.89M
O/S68.76M
Vol
$ Vol
RVOL
Inst Own100.9%
SI26.5%
Earnings
Dilution
Tyra Biosciences, Inc. logoNASDAQ:TYRA$21.07-1.91%
Phase Distribution
7 lead-sponsored trials·7 active·0 completed
Phase 13
Phase 1/21
Phase 23
Status Overview
Recruiting4
Active, not recruiting3

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 2
    Recruiting

    A Study of TYRA-300 in Children With Achondroplasia: BEACH301

    TYRA-300 0.125 mg/kg, TYRA-300 0.25 mg/kg

    Achondroplasia

    Enrollment
    92
    Start
    Mar 2025
    Primary Completion
    Jan 2030est.
    Completion
    Jun 2030est.
    NCT06842355
  • Phase 2
    Recruiting

    Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

    TYRA-300 60mg, TYRA-300 50mg

    Low-grade NMIBC, FGFR Gene Amplification +4

    Enrollment
    90
    Start
    Jun 2025
    Primary Completion
    Feb 2028est.
    Completion
    Sep 2028est.
    NCT06995677
  • Phase 2
    Recruiting

    Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma

    Dabogratinib (TYRA-300) 60mg, Dabogratinib (TYRA-300) 80mg

    Low Grade Upper Tract Urothelial Carcinoma

    Enrollment
    285
    Start
    Dec 2025
    Primary Completion
    Oct 2030est.
    Completion
    Nov 2030est.
    NCT07265947
  • Phase 1/2
    Active, not recruiting

    Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

    TYRA-300

    Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma +12

    Enrollment
    310
    Start
    Nov 2022
    Primary Completion
    Nov 2026est.
    Completion
    Jun 2027est.
    NCT05544552
  • Phase 1
    Active, not recruiting

    A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult Participants

    TYRA-300-B01

    Healthy

    Enrollment
    60
    Start
    Oct 2023
    Primary Completion
    May 2025est.
    Completion
    Jul 2025est.
    NCT06006702
  • Phase 1
    Active, not recruiting

    Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

    Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles, Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles

    Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma +2

    Enrollment
    40
    Start
    Nov 2023
    Primary Completion
    Mar 2027est.
    Completion
    Sep 2027est.
    NCT06160752
  • Phase 1
    Recruiting

    Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

    TYRA-430

    Metastatic Hepatocellular Carcinoma, Solid Tumors +9

    Enrollment
    125
    Start
    Apr 2025
    Primary Completion
    Jan 2028est.
    Completion
    Sep 2028est.
    NCT06915753
Search ClinicalTrials.gov for “Tyra Biosciences”